Tuzulby is a medicine used to treat attention deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17 years. It is used as part of a comprehensive treatment strategy that typically involves psychological, educational and other interventions and is used when these measures alone do not control their symptoms well enough. Tuzulby contains the active substance methylphenidate hydrochloride and is a ‘hybrid’ medicine. This means that it is similar to a ‘reference medicine’ containing the same active substance, but there are differences between the two. Tuzulby tablets release the active substance over a longer period of time than the reference medicine does. The reference medicine is Ritalin.
Therapeutic Indication
### Therapeutic indication Tuzulby is indicated as part of a comprehensive treatment programme for attention-deficit / hyperactivity disorder (ADHD) in children and adolescents 6-17 years old when remedial measures alone prove insufficient. Treatment must be under the supervision of a specialist in childhood behavioural disorders. Diagnosis should be made according to Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) criteria or the guidelines in International Classification of Diseases, Tenth Revision (ICD-10) and should be based on a complete history and evaluation of the patient. Diagnosis cannot be made solely on the presence of one or more symptoms.
Therapeutic Area (MeSH)
ATC Code
N06BA04
ATC Item
methylphenidate
Pharmacotherapeutic Group
Psychoanaleptics
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| methylphenidate hydrochloride | N/A | 哌甲酯 |
EMA Name
Tuzulby
Medicine Name
Tuzulby
Aliases
N/ANo risk management plan link.
